4.7 Article

Risk of COVID-19 Infection and of Severe Complications Among People With Epilepsy A Nationwide Cohort Study

期刊

NEUROLOGY
卷 98, 期 19, 页码 E1886-E1892

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000200195

关键词

-

资金

  1. Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [NRF-2020R1I1A1A01060447, NRF-2021R1F1A1048113]

向作者/读者索取更多资源

The presence of epilepsy does not increase susceptibility to COVID-19 infection or mortality related to the infection. However, patients with epilepsy have an increased risk of severe complications after COVID-19 infection, suggesting the need for careful management and monitoring.
Background and Objectives The goal of this work was to evaluate whether patients with epilepsy were more susceptible to coronavirus disease 2019 (COVID-19) infection and at greater risk of severe complications when infected with COVID-19 compared with patients without epilepsy. Methods Weincluded participants who underwent at least 1 severe acute respiratory syndrome coronavirus 2 real-time reverse-transcription PCR test between January 1 and June 4, 2020, from the Korean nationwideCOVID-19 dataset. Epilepsy was defined according to the presence of diagnostic code in health claims data before the COVID-19 diagnosis. To investigate the association between epilepsy and the susceptibility for or severe complications of COVID-19, a 1:6 ratio propensity score matching (PSM) and logistic regression analysis were performed. Severe complications withCOVID-19 infection were defined as a composite of the incidence ofmechanical ventilation, intensive care unit admission, and death within 2 months after COVID-19 diagnosis. Results Among 212,678 study participants who underwent a COVID-19 test, 3,919 (1.8%) had a history of epilepsy. After PSM, there was no significant difference in COVID-19 PCR positivity according to epilepsy history (odds ratio [OR] 0.86, 95% CI 0.67-1.11). Of the 7,713 individuals with confirmed COVID-19 infection, 72 (0.9%) had a history of epilepsy. Among the patients with COVID-19, severe complications occurred in 444 (5.8%) individuals. After PSM, the presence of epilepsy was associated with the occurrence of severe complications after COVID-19 infection (OR 2.05, 95% CI 1.04-4.04). Mortality after COVID-19 infection did not differ according to the presence of epilepsy history (OR 1.55, 95% CI 0.65-3.70). Discussion The presence of epilepsy was not associated with increased susceptibility to COVID-19 infection or mortality related to the infection. However, there was an increased risk of severe complications with COVID-19 in patients with epilepsy; therefore, careful management and monitoring may be necessary.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据